GlassScriptPhysician profile
Omid Roostaeyan
NPI 1164929774
$4,015.97
in general payments reported to CMS, 2019-2025
34 companies · $437 in 2025
The $437 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $190 · 2020: $14.82 · 2021: $447 · 2022: $1,122 · 2023: $743 · 2024: $1,062 · 2025: $437.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,241.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $908.85 | 2021-2025 | |
| Abbvie INC. | $488.48 | 2021-2025 | Qulipta, Ubrelvy |
| Abbott Laboratories | $408.66 | 2022-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $407.61 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $306.07 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Glaxosmithkline, LLC. | $208.52 | 2022-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $201.13 | 2021-2024 | Rybelsus, Ozempic, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $130.50 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.38 | 2022-2024 | Jardiance |
| Dexcom, INC. | $90.45 | 2022-2023 | Dexcom G6 Transmitter |
| Takeda Pharmaceuticals U.S.A., INC. | $68.29 | 2021-2022 | |
| Sanofi Pasteur INC. | $66.44 | 2022-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $55.88 | 2022 | |
| Merck Sharp & Dohme LLC | $54.63 | 2020-2022 | |
| Corium, LLC | $47.94 | 2022-2023 | Azstarys |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $42.70 | 2022-2024 | Qelbree |
| Amgen INC. | $39.40 | 2022-2023 | Prolia, Evenity |
| Nestle Healthcare Nutrition INC. | $35.84 | 2022-2023 | |
| Exeltis, USA INC. | $34.38 | 2021-2025 | Slynd |
| Dynavax Technologies Corporation | $34.05 | 2022-2024 | Heplisav-B |
| Nevro Corp. | $34.03 | 2022 | |
| Idorsia Pharmaceuticals US INC | $31.26 | 2022-2023 | Quviviq |
| Astellas Pharma US INC | $24.97 | 2024 | Veozah |
| Inspire Medical Systems, INC. | $21.88 | 2023 | Inspire |
| Sumitomo Pharma America, INC. | $19.23 | 2024 | Gemtesa |
| Medtronic, INC. | $18.43 | 2024 | Intellis Adaptivestim |
| Aimmune Therapeutics, INC. | $17.46 | 2024 | |
| Genentech USA, INC. | $17.21 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.69 | 2025 | |
| Biohaven Pharmaceuticals, INC. | $14.12 | 2021 | |
| Nabriva Therapeutics, Plc | $13.97 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2021 | |
| Sanofi-Aventis U.S. LLC | $13.46 | 2022 | |
| Organon LLC | $8.40 | 2025 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Roostaeyan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.